345 related articles for article (PubMed ID: 19515014)
1. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
2. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.
Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
Curr Drug Metab; 2009 Dec; 10(10):1075-126. PubMed ID: 20167001
[TBL] [Abstract][Full Text] [Related]
3. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
[TBL] [Abstract][Full Text] [Related]
4. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation.
Nair PC; Burns K; Chau N; McKinnon RA; Miners JO
J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634
[TBL] [Abstract][Full Text] [Related]
6. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
He SM; Zhou ZW; Li XT; Zhou SF
Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.
Hutzler JM; Balogh LM; Zientek M; Kumar V; Tracy TS
Drug Metab Dispos; 2009 Jan; 37(1):59-65. PubMed ID: 18838506
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
[TBL] [Abstract][Full Text] [Related]
9. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.
Lai XS; Yang LP; Li XT; Liu JP; Zhou ZW; Zhou SF
Curr Drug Metab; 2009 Nov; 10(9):1009-47. PubMed ID: 20214592
[TBL] [Abstract][Full Text] [Related]
10. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.
Wang B; Zhou SF
Curr Med Chem; 2009; 16(31):4066-218. PubMed ID: 19754423
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Wang B; Wang J; Huang SQ; Su HH; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
[TBL] [Abstract][Full Text] [Related]
13. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.
Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H
Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280
[TBL] [Abstract][Full Text] [Related]
14. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
Ahlström MM; Ridderström M; Zamora I
J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
[TBL] [Abstract][Full Text] [Related]
16. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
18. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor.
Gerbal-Chaloin S; Daujat M; Pascussi JM; Pichard-Garcia L; Vilarem MJ; Maurel P
J Biol Chem; 2002 Jan; 277(1):209-17. PubMed ID: 11679585
[TBL] [Abstract][Full Text] [Related]
20. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
